Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCytoMed Therapeutics Limited Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.04 | -$0.04 | -$0.04 |
| Q2 2025 | 1 | -$0.04 | -$0.04 | -$0.04 |
CytoMed Therapeutics Limited Earnings Date And Information
CytoMed Therapeutics Limited last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of 105.71 K for the quarter and had revenue of 52.01 K for the year. CytoMed Therapeutics Limited has generated $0 earnings per share over the last year ($-0.16 diluted earnings per share) and currently has a price-to-earnings ratio of -5.53. CytoMed Therapeutics Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 30th, 2025 based on prior year's report dates.
CytoMed Therapeutics Limited Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2025 | Q2 2025 | N/A | -$0.07 | N/A | $130.00 K | $105.71 K |
| 03/31/2025 | Q1 2025 | N/A | -$0.07 | N/A | N/A | $100.04 K |
| 04/28/2025 | Q4 2024 | N/A | -$0.09 | N/A | N/A | $52.42 K |
| 09/30/2024 | Q3 2024 | N/A | -$0.05 | N/A | $0 | $108.62 K |
| 06/29/2024 | Q2 2024 | N/A | -$0.07 | N/A | $156.00 K | $82.67 K |
| 03/31/2024 | Q1 2024 | N/A | -$0.04 | N/A | N/A | $83.11 K |
| 04/22/2024 | Q4 2023 | N/A | -$0.06 | N/A | N/A | $84.69 K |
| 09/29/2023 | Q3 2023 | N/A | -$0.06 | N/A | N/A | $81.75 K |
| 06/29/2023 | Q2 2023 | N/A | -$0.14 | N/A | N/A | $105.08 K |
| 03/30/2023 | Q1 2023 | N/A | -$0.08 | N/A | N/A | $106.79 K |
| 05/01/2023 | Q4 2022 | N/A | -$0.14 | N/A | N/A | $108.02 K |
| 09/29/2022 | Q3 2022 | N/A | -$0.09 | N/A | N/A | $100.74 K |
| 06/30/2022 | Q2 2022 | N/A | -$0.09 | N/A | N/A | $0 |
| 03/31/2022 | Q1 2022 | N/A | -$0.05 | N/A | N/A | $27.50 K |
| 12/31/2021 | Q4 2021 | N/A | -$0.11 | N/A | N/A | $0 |
| 09/30/2021 | Q3 2021 | N/A | -$0.05 | N/A | N/A | $31.38 K |
| 06/29/2021 | Q2 2021 | N/A | -$0.11 | N/A | N/A | $0 |
| 03/31/2021 | Q1 2021 | N/A | -$0.06 | N/A | N/A | $10.64 K |
| 12/31/2020 | Q4 2020 | N/A | -$0.09 | N/A | N/A | $22.51 K |
| 09/30/2020 | Q3 2020 | N/A | -$0.10 | N/A | N/A | $21.78 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
CytoMed Therapeutics Limited Earnings: FAQ's
CytoMed Therapeutics Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 30th, 2025 based offlast year's report dates.
The conference call for CytoMed Therapeutics Limited's latest earnings report can be listened to online.
The conference call transcript for CytoMed Therapeutics Limited's latest earnings report can be read online.
CytoMed Therapeutics Limited (:GDTC) has a recorded annual revenue of $52.01 K.
CytoMed Therapeutics Limited (:GDTC) has a recorded net income of $-1,883,178.CytoMed Therapeutics Limited has generated $-0.16 earnings per share over the last four quarters.
CytoMed Therapeutics Limited (:GDTC) has a price-to-earnings ratio of -5.53 and price/earnings-to-growth ratio is 1.55.